Cinclus Pharma Holding AB ((SE:CINPHA)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Cinclus Pharma Holding AB is conducting a Phase 3 clinical trial titled A Randomized, Phase 3, Double-blind, Double-dummy, Active Comparator-controlled Multicenter Study to Evaluate the Efficacy and Safety of 2 Doses of Linaprazan Glurate Compared to Lansoprazole in 4 or 8 Weeks Healing in Participants With Erosive Esophagitis (EE) Due to Gastroesophageal Reflux Disease (GERD) of Los Angeles (LA) Grades A to D. The study aims to assess the healing efficacy and safety of linaprazan glurate versus lansoprazole in treating erosive esophagitis caused by GERD.
Intervention/Treatment: The study tests two doses of linaprazan glurate (50 mg twice daily and 50 mg once daily) against lansoprazole (30 mg once daily). Linaprazan glurate is being evaluated for its potential to heal erosive esophagitis and reduce heartburn symptoms more effectively than lansoprazole.
Study Design: This randomized, double-blind, active comparator-controlled trial involves three groups, each receiving different treatments. Participants and researchers are unaware of the group assignments, ensuring unbiased results. The primary purpose is to treat erosive esophagitis in GERD patients.
Study Timeline: The study is not yet recruiting, with an estimated start date in September 2025. The study was first submitted in June 2025, with the last update also in June 2025. These dates are crucial for tracking the study’s progress and anticipated outcomes.
Market Implications: This study could significantly impact Cinclus Pharma’s stock performance if linaprazan glurate proves more effective than lansoprazole, potentially positioning the company as a leader in GERD treatment. Investors should watch for developments, as positive results could shift market dynamics and influence competitor strategies.
The study is ongoing, with further details available on the ClinicalTrials portal.